Stock XTCY XTACY THERAPEUTICS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Xtacy Therapeutics Corp. Stock

Equities

XTCY

CA98423G1072

Investment Management & Fund Operators

Market Closed - Canadian Securities Exchange
Other stock markets
 02:13:17 2024-04-16 pm EDT 		5-day change 1st Jan Change
0.03 CAD -25.00% Intraday chart for Xtacy Therapeutics Corp. -25.00% -33.33%
Apr. 17 Xtacy Therapeutics Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Apr. 15 Xtacy Therapeutics Corp. Reports Earnings Results for the Full Year Ended September 30, 2023 CI

Financials

Sales 2022 - Sales 2023 - Capitalization 2.46M 3.39M
Net income 2022 -1M -1.38M Net income 2023 - 0 EV / Sales 2022 -
Net Debt 2022 25.37K 34.93K Net Debt 2023 16.7K 23K EV / Sales 2023 -
P/E ratio 2022
-3.97 x
P/E ratio 2023
-4.19 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 89.2%
More Fundamentals * Assessed data

Chart Xtacy Therapeutics Corp.

Dynamic Chart

Latest news about Xtacy Therapeutics Corp.

Xtacy Therapeutics Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Xtacy Therapeutics Corp. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
Xtacy Therapeutics Corp. Expands MDMA Platform Pharmaceutical Grade Psychedelic Solutions to Solve Unmet Medical Needs CI
Global Wellness Strategies Inc. will Change its Name to XTACY Therapeutics Corp CI
Global Wellness Strategies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
Global Wellness Strategies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023 CI
Global Wellness Strategies Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022 CI
Global Wellness Strategies Inc. Reports Earnings Results for the Full Year Ended September 30, 2022 CI
Global Wellness Strategies Inc. Auditor Raises 'Going Concern' Doubt CI
Global Wellness Strategies Inc. Announces Formation of Wholly Owned Pharma Subsidiary Focused on Clinical Trials CI
Global Wellness Strategies Effervescent Cannabis Products Approved to Launch GWS Achieves Major Milestone Partnering with Hempsana Holdings CI
Global Wellness Strategies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022 CI
Global Wellness Strategies Inc. Signs Custom Manufacturing Agreement with Hempsana Holdings CI
Global Wellness Strategies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022 CI
Global Wellness Strategies Inc. Announces Shanti Therapeutics Mdma Clinical Trial Update CI
More news

Press releases Xtacy Therapeutics Corp.

XTACY Therapeutics Announces Debt Settlement NE
Global Wellness Strategies : Voting Instruction Form (“VIF”) – Annual General Meeting to be held on Wednesday, August 16, 2023 PU
Global Wellness Strategies : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 16, 2023 PU
Global Wellness Strategies : GWS NEWS RELEASE PU
Global Wellness Strategies : Files Annual Statements September 2022 PU
More press releases

Quotes and Performance

1 day-25.00%
1 week-25.00%
Current month-25.00%
1 month-50.00%
3 months-40.00%
6 months-33.33%
Current year-33.33%
More quotes

Highs and lows

1 week
0.03
Extreme 0.03
0.04
1 month
0.03
Extreme 0.03
0.07
Current year
0.03
Extreme 0.03
0.10
1 year
0.02
Extreme 0.02
0.19
3 years
0.02
Extreme 0.02
0.50
5 years
0.02
Extreme 0.02
0.80
10 years
0.02
Extreme 0.02
2.80
More quotes

Managers and Directors - Xtacy Therapeutics Corp.

Managers TitleAgeSince
Meris Kott CEO
 Chief Executive Officer - 17-11-29
Lindsey R. Perry DFI
 Director of Finance/CFO 70 19-04-09
Monita Faris SEC
 Corporate Secretary - -
Members of the board TitleAgeSince
Lindsey R. Perry DFI
 Director of Finance/CFO 70 19-04-09
Meris Kott CEO
 Chief Executive Officer - 17-11-29
Ashleigh Vogstad BRD
 Director/Board Member - 19-10-29
More insiders

Quotes

Date Price Change Volume
24-04-16 0.03 -25.00% 30,000

Delayed Quote Canadian Securities Exchange, April 16, 2024 at 02:13 pm EDT

More quotes

Company Profile

XTACY Therapeutics Corp. is a Canada-based prospect generator that provides high growth companies with financial, operational, and management assistance in the fast-growing market for consumer wellness products. The Company's investment strategy is focused on the specific areas of pain, depression and mental illness. The focus of the Company is on global wellness, psychedelics, mycology, hemp and cannabidiol (CBD), healthcare-related target companies and their clinical studies and trials. By investing in techniques, such as micro-dosing using organic compounds and synthetic molecules, the Company is focusing on the research with the aim of providing wellness benefits with less side effects for people and the planet.
Sector
Investment Management & Fund Operators
Calendar
2024-05-29 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Other Investment Management & Fund Operators

1st Jan change Capi.
XTACY THERAPEUTICS CORP. Stock Xtacy Therapeutics Corp.
-33.33% 1.19M
BLACKROCK, INC. Stock BlackRock, Inc.
-7.95% 112B
UBS GROUP AG Stock UBS Group AG
-1.11% 90.24B
APOLLO GLOBAL MANAGEMENT, INC. Stock Apollo Global Management, Inc.
+15.14% 61.07B
BROOKFIELD CORPORATION Stock Brookfield Corporation
-0.04% 58.93B
AMERIPRISE FINANCIAL, INC. Stock Ameriprise Financial, Inc.
+8.64% 41.26B
BANK OF NEW YORK MELLON CORPORATION (THE) Stock Bank of New York Mellon Corporation (The)
+6.15% 40.73B
3I GROUP PLC Stock 3i Group plc
+17.55% 34.1B
T. ROWE PRICE GROUP INC. Stock T. Rowe Price Group Inc.
+0.96% 24.91B
STATE STREET CORPORATION Stock State Street Corporation
-5.71% 21.95B
Other Investment Management & Fund Operators
  1. Stock Market
  2. Equities
  3. XTCY Stock